International Congress on Hematologic Malignancies (HEM) 2024
Efficacy and Safety Is Maintained in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan for Up to 3 Years
Access Resources
Human Factors Validation Study for a Wearable, Single-Use Injector
Access Resources